SEARCH
Subscribe
Track all markets on TradingView

Beleave Takes an Important First Step into Cannabis Oil

Published:

Reading time: 3 min.

In this market news, Beleave Inc. (CSE:BE), one of the Canadian marijuana stocks, said it has received authorization from Health Canada to sell cannabis oil products

SmallCapPower | January 21, 2019: Beleave Inc. (CSE:BE) (OTCQX:BLEVF), one of the Canadian cannabis stocks, announced recently that its wholly-owned subsidiary, Beleave Kannabis Corp., has received authorization from Health Canada to sell cannabis oil products from January 11, 2019. Health Canada has granted an amended license with modified conditions allowing the sale of cannabis oil under the Cannabis Regulations.

For Our Complete Coverage Of Canadian Marijuana Stocks Click Here  

Beleave Inc. Chief Science Officer Roger Ferreira said, “This license is pivotal to us meeting our goals in 2019, while driving product innovation and augmenting our research and development initiatives. Oils will continue to make up a larger part of the cannabis market, especially as we ramp up for the regulatory changes coming in 2019. Receiving our sales authorization allows us to provide a wider array of products while providing Beleave with higher margins than dried flower.”

Win Big With Our Small Cap Picks

 

Beleave is a fully-licensed, vertically-integrated Canadian cannabis company, cultivating high-quality cannabis flower, oil and extracts. Beleave has established technical partnerships with universities to develop pharma-grade extracts and derivatives. The Company has developed new product lines, such as cannabis-infused powder and sugar products, for 2019 in anticipation of legalization of food and beverage-based cannabis products.

On the expansion front, Beleave has established a network of medical cannabis clinics in Ontario and Quebec under the Medi- Green banner. Beleave has a majority ownership of Procannmed S.A.S to produce and distribute medical cannabis in Colombia, and to grab a foothold in Latin America. The Company also partnered with Canymed GmbH to penetrate the European medical market.

Beleave stock trades at a market capitalization of C$59.7 million with a price-to-book multiple of 3.2x.

Disclosure: Neither the author nor his family own shares in the company mentioned above.

To read our full disclosure, please click on the button below:

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
jsteppke
jsteppke

Related articles

Recent articles

© SmallCapPower 2024